Related Experiment Video
Updated: Aug 26, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Can we afford to eliminate restenosis? Can we afford not to?
Dan Greenberg1, Ameet Bakhai, David J Cohen
1Harvard Clinical Research Institute, Boston, Massachusetts, USA.
Insights
Drug-eluting stents (DES) significantly reduce restenosis after coronary stenting, offering potential cost-effectiveness despite initial concerns. This review examines the economic impact of restenosis and the value of DES in cardiovascular care.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Health Economics
Background:
- Coronary stenting is the primary percutaneous coronary revascularization method.
- Bare metal stents have high restenosis rates, increasing healthcare costs.
- Drug-eluting stents (DES) show promise in reducing restenosis.
Discussion:
- This article reviews the economic burden of restenosis.
- It explores the cost-effectiveness of DES from a healthcare system perspective.
- Patient, lesion, and provider factors influencing DES outcomes are considered.
Key Insights:
- DES demonstrate significant reductions in restenosis compared to bare metal stents.
- The economic impact of restenosis necessitates evaluating cost-effective alternatives.
- Understanding factors influencing DES performance is crucial for optimal implementation.
Outlook:
- Further research on long-term cost-effectiveness of DES is warranted.
- Personalized approaches considering patient and lesion characteristics may optimize DES therapy.
- DES represent a promising advancement in managing coronary artery disease.
Abstract:
Over the past decade, coronary stenting has emerged as the dominant form of percutaneous coronary revascularization. However, bare metal stents remain limited by a high incidence of restenosis, leading to frequent repeat revascularization procedures and substantial economic burden. Antiproliferative drug-eluting stents (DES) have recently demonstrated dramatic reductions in rates of restenosis, compared with conventional stenting, but important concerns about their costs have been raised. In this article, we summarize current evidence on the economic impact of restenosis and explore the potential benefits and economic outcomes of DES. In addition to examining the long-term costs of this promising technology, we consider the potential cost-effectiveness of DES from a health care system perspective and the impact of specific patient, lesion, and provider characteristics on these parameters.
More Related Videos
09:46Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
Published on: September 14, 2009
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Aneurysm III: Interprofessional Care
Angina IV: Management